153 related articles for article (PubMed ID: 37252102)
21. Method for Assaying the Lipid Kinase Phosphatidylinositol-5-phosphate 4-kinase α in Quantitative High-Throughput Screening (qHTS) Bioluminescent Format.
Davis MI; Sasaki AT; Simeonov A
Methods Mol Biol; 2016; 1376():1-9. PubMed ID: 26552670
[TBL] [Abstract][Full Text] [Related]
22. Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential.
Ghigo A; Hirsch E
Recent Pat Inflamm Allergy Drug Discov; 2008 Jan; 2(1):1-10. PubMed ID: 19075988
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Potent and Exquisitely Selective Inhibitors of Kinase CK1 with Tunable Isoform Selectivity.
Němec V; Khirsariya P; Janovská P; Moyano PM; Maier L; Procházková P; Kebková P; Gybel' T; Berger BT; Chaikuad A; Reinecke M; Kuster B; Knapp S; Bryja V; Paruch K
Angew Chem Int Ed Engl; 2023 Mar; 62(11):e202217532. PubMed ID: 36625768
[TBL] [Abstract][Full Text] [Related]
24. Exploring the potential of PI3K inhibitors for inflammation and cancer.
Crabbe T
Biochem Soc Trans; 2007 Apr; 35(Pt 2):253-6. PubMed ID: 17371252
[TBL] [Abstract][Full Text] [Related]
25. Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors.
Uba Aİ; Yelekçi K
Turk J Biol; 2017; 41(6):901-918. PubMed ID: 30814855
[TBL] [Abstract][Full Text] [Related]
26. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
[TBL] [Abstract][Full Text] [Related]
27. Pharmacoinformatic Approaches to Design Novel Inhibitors of Protein Kinase B Pathways in Cancer.
Akhtar N; Jabeen I
Curr Cancer Drug Targets; 2018; 18(9):830-846. PubMed ID: 28669343
[TBL] [Abstract][Full Text] [Related]
28. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
Hanan EJ; Braun MG; Heald RA; MacLeod C; Chan C; Clausen S; Edgar KA; Eigenbrot C; Elliott R; Endres N; Friedman LS; Gogol E; Gu XH; Thibodeau RH; Jackson PS; Kiefer JR; Knight JD; Nannini M; Narukulla R; Pace A; Pang J; Purkey HE; Salphati L; Sampath D; Schmidt S; Sideris S; Song K; Sujatha-Bhaskar S; Ultsch M; Wallweber H; Xin J; Yeap S; Young A; Zhong Y; Staben ST
J Med Chem; 2022 Dec; 65(24):16589-16621. PubMed ID: 36455032
[TBL] [Abstract][Full Text] [Related]
29. Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor.
Stachel SJ; Berger R; Nomland AB; Ginnetti AT; Paone DV; Wang D; Puri V; Lange H; Drott J; Lu J; Marcus J; Dwyer MP; Suon S; Uslaner JM; Smith SM
ACS Med Chem Lett; 2018 Aug; 9(8):815-820. PubMed ID: 30128073
[TBL] [Abstract][Full Text] [Related]
30. Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.
Ernst JT; Liu M; Zuccola H; Neubert T; Beaumont K; Turnbull A; Kallel A; Vought B; Stamos D
Bioorg Med Chem Lett; 2014 Jan; 24(1):204-8. PubMed ID: 24332488
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
Gupta R; Ambasta RK; Kumar P
Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a new series of PI3K-δ inhibitors from Virtual Screening.
Fradera X; Deng Q; Achab A; Garcia Y; Kattar SD; McGowan MA; Methot JL; Wilson K; Zhou H; Shaffer L; Goldenblatt P; Tong V; Augustin MA; Altman MD; Lesburg CA; Shah S; Katz JD
Bioorg Med Chem Lett; 2021 Jun; 42():128046. PubMed ID: 33865969
[TBL] [Abstract][Full Text] [Related]
33. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3.
Angell RM; Atkinson FL; Brown MJ; Chuang TT; Christopher JA; Cichy-Knight M; Dunn AK; Hightower KE; Malkakorpi S; Musgrave JR; Neu M; Rowland P; Shea RL; Smith JL; Somers DO; Thomas SA; Thompson G; Wang R
Bioorg Med Chem Lett; 2007 Mar; 17(5):1296-301. PubMed ID: 17194588
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.
Schmitt C; Kail D; Mariano M; Empting M; Weber N; Paul T; Hartmann RW; Engel M
PLoS One; 2014; 9(3):e87851. PubMed ID: 24676346
[TBL] [Abstract][Full Text] [Related]
35. Structural Requirements and Docking Analysis of Amidine-Based Sphingosine Kinase 1 Inhibitors Containing Oxadiazoles.
Houck JD; Dawson TK; Kennedy AJ; Kharel Y; Naimon ND; Field SD; Lynch KR; Macdonald TL
ACS Med Chem Lett; 2016 May; 7(5):487-92. PubMed ID: 27190598
[TBL] [Abstract][Full Text] [Related]
36. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
Smith AL; D'Angelo ND; Bo YY; Booker SK; Cee VJ; Herberich B; Hong FT; Jackson CL; Lanman BA; Liu L; Nishimura N; Pettus LH; Reed AB; Tadesse S; Tamayo NA; Wurz RP; Yang K; Andrews KL; Whittington DA; McCarter JD; Miguel TS; Zalameda L; Jiang J; Subramanian R; Mullady EL; Caenepeel S; Freeman DJ; Wang L; Zhang N; Wu T; Hughes PE; Norman MH
J Med Chem; 2012 Jun; 55(11):5188-219. PubMed ID: 22548365
[TBL] [Abstract][Full Text] [Related]
37. Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration.
Perry MWD; Björhall K; Bonn B; Carlsson J; Chen Y; Eriksson A; Fredlund L; Hao H; Holden NS; Karabelas K; Lindmark H; Liu F; Pemberton N; Petersen J; Rodrigo Blomqvist S; Smith RW; Svensson T; Terstiege I; Tyrchan C; Yang W; Zhao S; Öster L
J Med Chem; 2017 Jun; 60(12):5057-5071. PubMed ID: 28520415
[TBL] [Abstract][Full Text] [Related]
38. Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation.
Pai P; Kumar A; Shetty MG; Kini SG; Krishna MB; Satyamoorthy K; Babitha KS
J Mol Model; 2022 Apr; 28(5):119. PubMed ID: 35419753
[TBL] [Abstract][Full Text] [Related]
39. A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth.
Wang X; Li JP; Yang Y; Ding J; Meng LH
Acta Pharmacol Sin; 2013 Sep; 34(9):1201-7. PubMed ID: 23892273
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.
Lountos GT; Tropea JE; Zhang D; Jobson AG; Pommier Y; Shoemaker RH; Waugh DS
Protein Sci; 2009 Jan; 18(1):92-100. PubMed ID: 19177354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
